Ducrocq G, Bhatt D L, Labreuche J, Corbalan R, Porath A, Gao R, Panchenko E, Liau C S, Ikeda Y, Goto S, Amarenco P, Steg P G
Université Paris-Diderot, Sorbonne Paris Cité, France; AP-HP, Hopital Bichat - Paris, France; INSERM U-698, France
VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, USA.
Eur J Prev Cardiol. 2014 Dec;21(12):1509-16. doi: 10.1177/2047487313501278. Epub 2013 Aug 21.
There are major differences in the prevalence and management of patients with atherothrombotic disease including coronary artery disease (CAD), cerebrovascular disease (CVD) and peripheral artery disease (PAD) across different geographical regions. There is, however, little data allowing comparisons of management and outcomes across broad geographic regions. We aimed to describe geographical differences in baseline characteristics, management and outcomes in stable outpatients with established atherothrombotic disease.
From the REACH Registry of atherothrombosis, patients with documented CAD, PAD or CVD and with 4-year follow-up were included. Baseline characteristics, treatments and 4-year outcomes were recorded. Event rates were compared between geographical regions and were adjusted for risk scores predicting ischemic and bleeding events. The analyses of baseline characteristics and medications according to geographical region showed marked differences. For the composite primary outcome (cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke), rates ranged from 12.1% in Japan to 18.2% in Eastern Europe. After adjustment, substantial variations remained: taking North America as a reference, patients from Western Europe and Japan had a lower risk of primary outcome event (hazard ratio (HR) 0.93; p = 0.045, and HR = 0.67; p < 0.001 respectively) whereas patients from Eastern Europe had a higher risk (HR = 1.24; p < 0.001). There were no obvious differences between patients from North America and those from Latin America, the Middle East and Asia.
There are important variations in the outcomes of patients with atherothrombotic across geographic regions. These observations have important implications for public health and clinical research.
不同地理区域的动脉粥样硬化血栓形成疾病患者(包括冠状动脉疾病(CAD)、脑血管疾病(CVD)和外周动脉疾病(PAD))在患病率和管理方面存在重大差异。然而,几乎没有数据可用于比较广泛地理区域的管理情况和结局。我们旨在描述已确诊动脉粥样硬化血栓形成疾病的稳定门诊患者在基线特征、管理和结局方面的地理差异。
从动脉粥样硬化血栓形成的REACH注册研究中,纳入有记录的CAD、PAD或CVD且有4年随访的患者。记录基线特征、治疗方法和4年结局。比较不同地理区域的事件发生率,并根据预测缺血和出血事件的风险评分进行调整。根据地理区域对基线特征和药物治疗的分析显示出显著差异。对于复合主要结局(心血管死亡、非致命性心肌梗死(MI)和非致命性卒中),发生率在日本为12.1%,在东欧为18.2%。调整后,仍存在很大差异:以北美为参照,西欧和日本的患者发生主要结局事件的风险较低(风险比(HR)分别为0.93;p = 0.045,以及HR = 0.67;p < 0.001),而东欧患者的风险较高(HR = 1.24;p < 0.001)。北美患者与拉丁美洲、中东和亚洲患者之间没有明显差异。
动脉粥样硬化血栓形成疾病患者的结局在不同地理区域存在重要差异。这些观察结果对公共卫生和临床研究具有重要意义。